Weekly Investment Analysts’ Ratings Updates for NuCana (NCNA)

Share on StockTwits

Several analysts have recently updated their ratings and price targets for NuCana (NASDAQ: NCNA):

  • 4/13/2019 – NuCana was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “
  • 4/12/2019 – NuCana was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $19.00 price target on the stock. According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “
  • 4/3/2019 – NuCana was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “
  • 3/30/2019 – NuCana was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “
  • 3/20/2019 – NuCana was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “

NuCana stock traded down $0.45 during trading hours on Thursday, reaching $13.55. 12,330 shares of the company’s stock were exchanged, compared to its average volume of 80,176. NuCana PLC has a twelve month low of $10.37 and a twelve month high of $32.00. The company has a market cap of $427.74 million, a P/E ratio of -23.77 and a beta of 4.33.

NuCana (NASDAQ:NCNA) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.06. Analysts forecast that NuCana PLC will post -1.07 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Partner Fund Management L.P. grew its stake in shares of NuCana by 14.9% in the 4th quarter. Partner Fund Management L.P. now owns 447,420 shares of the company’s stock valued at $6,488,000 after buying an additional 58,062 shares during the period. Alps Advisors Inc. lifted its position in NuCana by 30.6% in the 4th quarter. Alps Advisors Inc. now owns 73,678 shares of the company’s stock valued at $1,068,000 after acquiring an additional 17,259 shares in the last quarter. Finally, Rothschild Investment Corp IL bought a new position in NuCana in the 1st quarter valued at about $211,000. Hedge funds and other institutional investors own 34.02% of the company’s stock.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.

Recommended Story: What is the Stochastic Momentum Index (SMI)?

Receive News & Ratings for NuCana PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

BitDegree  Reaches One Day Volume of $619.00
BitDegree Reaches One Day Volume of $619.00
Online  Trading Up 32.5% Over Last 7 Days
Online Trading Up 32.5% Over Last 7 Days
HOQU Reaches Market Cap of $1.22 Million
HOQU Reaches Market Cap of $1.22 Million
Critical Contrast: COMSCORE  vs. Conduent
Critical Contrast: COMSCORE vs. Conduent
COZ  Achieves Market Cap of $652.80 Million
COZ Achieves Market Cap of $652.80 Million
Blockchain Certified Data Token Price Hits $0.0554 on Exchanges
Blockchain Certified Data Token Price Hits $0.0554 on Exchanges


 
© 2006-2019 Zolmax.